Fanconi Anemia Complementation Group A

Hematology
3
Pipeline Programs
1
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Rocket Pharmaceuticals
4 programs
1
2
RP-L102Phase 21 trial
RP-L102Phase 21 trial
RP-L102Phase 11 trial
Safety and efficacy assessmentsN/A1 trial
Active Trials
NCT04437771Enrolling By Invitation9Est. Jan 2035
NCT03814408Unknown2Est. Mar 2022
NCT04069533Active Not Recruiting7Est. Feb 2025
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Rocket PharmaceuticalsRP-L102
Rocket PharmaceuticalsRP-L102
Rocket PharmaceuticalsRP-L102
Rocket PharmaceuticalsSafety and efficacy assessments

Clinical Trials (4)

Total enrollment: 23 patients across 4 trials

Gene Therapy for Fanconi Anemia, Complementation Group A

Start: Jul 2020Est. completion: May 20265 patients
Phase 2Active Not Recruiting

Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

Start: Nov 2019Est. completion: Feb 20257 patients
Phase 2Active Not Recruiting

A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

Start: Jan 2019Est. completion: Mar 20222 patients
Phase 1Unknown
NCT04437771Rocket PharmaceuticalsSafety and efficacy assessments

Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy

Start: Jun 2020Est. completion: Jan 20359 patients
N/AEnrolling By Invitation

Related Jobs in Hematology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space